Raymond James initiated coverage of Lumexa Imaging (LMRI) with an Outperform rating and $23 price target Lumexa Imaging is the #2 #2 U.S. public outpatient diagnostic imaging operator and the only pure-play public comp to RadNet (RDNT), the analyst tells investors in a research note. Lumexa has some elements to close the gap, including a better- outlined external growth strategy, more attractive local market fundamentals, and continued deleveraging, the firm says.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LMRI:
- Lumexa Imaging initiated with an Overweight at Wells Fargo
- Lumexa Imaging Holdings: Capitalizing on Outpatient Imaging Tailwinds with Sustainable Growth and Attractive Risk-Reward
- Lumexa Imaging initiated with a Buy at Jefferies
- Lumexa Imaging Holdings: Leveraging Outpatient Growth and JV Model to Drive Premium-Valued Expansion and Deleveraging Upside
- Lumexa Imaging Secures New Long-Term Senior Credit Facilities